[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![AponiaAnalytics Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1816152863069925376.png) aponia_analytics [@AponiaAnalytics](/creator/twitter/AponiaAnalytics) on x 4987 followers
Created: 2025-07-20 21:27:43 UTC

🦉 REWIND showed dulaglutide reduced MACE in lower-risk T2DM patients; benefits driven by nonfatal stroke. But XX% discontinued by study end. Tolerability remains a limiting factor in long-term outcomes.

#GLP1 #stroke $NVO $LLY $ZLDPF $VANI $HIMS $AZN


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947045781233344553/c:line.svg)

**Related Topics**
[manat](/topic/manat)
[hims](/topic/hims)
[$hims](/topic/$hims)
[$vani](/topic/$vani)
[$zldpf](/topic/$zldpf)
[$lly](/topic/$lly)
[longterm](/topic/longterm)
[$nvo](/topic/$nvo)

[Post Link](https://x.com/AponiaAnalytics/status/1947045781233344553)